• SNY

Earnings call: Sanofi reports robust Q3 sales and raises 2024 EPS guidance

Sanofi's Q3 2024 results show €13.4 billion in sales, driven by Dupixent and vaccines, leading to increased EPS guidance and negotiations to sell Opella stake.

• SNY

Sanofi profit growth beats market view on early start of vaccine sales

• AAPL
• AMZN
• GOOGL
• JP225
• MBGAF
• META
• MIWO00000PUS
• MSFT
• SNY
• STOXX
• TSLA
• USD/JPY

Morning Bid: Markets enter the eye of risk-event storm

Markets are set for volatility due to upcoming risk events, including mega-cap earnings and U.S. payrolls, amid a strengthening dollar and uncertain equity trends.

• SASY
• SNY

Sanofi and CD&R enter exclusive talks for Opella sale

Sanofi is negotiating to sell a controlling stake in its consumer healthcare unit, Opella, to CD&R, aiming to focus on innovative medicines and streamline its business.

• SNY

Sanofi in exclusive talks with CD&R over sale of $17 billion Opella

Sanofi is negotiating to sell a 50% stake in its consumer health division, Opella, to CD&R, while ensuring job security in France.

• SNY

Sanofi reaches deal on terms of sale of consumer health arm, say French government sources

Sanofi has sold a controlling stake in its consumer health unit Opella to Clayton Dubilier & Rice, ensuring job security in France amidst concerns over strategic asset loss.

• SNY

CD&R nears deal to buy Sanofi's consumer unit for $16 billion, source says

Sanofi is reportedly finalizing a sale of its consumer health unit to Clayton Dubilier & Rice for around 15 billion euros to boost drug development funding.

• CSLLY
• GSK
• SNY

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply

GSK, Sanofi, and CSL received $72 million from the U.S. government to boost bird flu vaccine production amid a recent outbreak affecting livestock and poultry.

• RECI
• SNY

Recordati shares jump on deal with Sanofi for Enjaymo rights

Recordati's shares rose post-deal with Sanofi for Enjaymo, a treatment for cold agglutinin disease, projecting significant revenue growth and strategic expansion in rare diseases.

• CI
• CVS
• LLY
• NVO
• SNY
• UNH

Texas attorney general sues insulin makers and pharmacy middlemen over high costs

Texas AG Ken Paxton has sued insulin manufacturers and PBMs for inflating insulin prices, alleging collusion to benefit from high costs, challenging prior FTC actions targeting only PBMs.